Axol Bioscience acquires ophthalmology business from Newcells Biotech

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of Newcells Biotech (Newcells), a leading drug discovery partner specializing in the development of in vitro models and bespoke assay services.

UK-Based Axol Bioscience Acquires Newcells’ Ophthalmology Business

Axol Bioscience, a provider of induced pluripotent stem cell (iPSC) technologies, nnounced the acquisition of the ophthalmology business of Newcells Biotech, a drug discovery partner specialising in advanced in vitro models and bespoke assay services. The acquisition includes Newcells’ specialist ophthalmology team, laboratory facilities and intellectual property related to its proprietary iPSC-derived retinal products and research services. Fin…

Axol buys Newcells’ ophthalmology business to grow drug discovery portfolio - European Biotechnology Magazine

Axol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models. The post Axol buys Newcells’ ophthalmology business to grow drug discovery portfolio appeared first on European Biotechnology Magazine.

Axol Bioscience acquires Newcells Biotech ophthalmology unit

Move expands iPSC‑derived retinal model portfolio and strengthens position in research